Page 63 - 8_04

Alicia Rodríguez Gascón, M.ª Ángeles Solinís Aspiazu, Ana del Pozo Rodríguez
34. del Pozo-Rodríguez A, Delgado D, Solinís MA, et al.
Solid lipid nanoparticles as potential tools for gene
therapy: in vivo protein expression after intravenous
administration. Int J Pharm 2010; 385: 157-62.
35. Delgado D, del Pozo-Rodríguez A, Solinís MA,
Bartkowiak A, Rodríguez-Gascón A. New gene
delivery system based on oligochitosan and solid lipid
nanoparticles: 'in vitro' and 'in vivo' evaluation. Eur J
Pharm Sci. 2013 Nov 20;50(3-4):484-91.
36. Battaglia L, Serpe L, Foglietta F, et al. Application of
lipid nanoparticles to ocular drug delivery. Expert
Opin Drug Deliv 2016; 24: 1-15.
37. Gottfried LF, Dean DA. Extracellular and Intracellular
Barriers to Non-Viral Gene Transfer. In: Wei M,
Good D, Eds. Novel Gene Therapy Approaches.
Croatia: InTech 2013; pp.75-88.
38. del Pozo-Rodríguez A, Delgado D, Solinís MA,
Gascón AR, Pedraz JL. Solid lipid nanoparticles for
retinal gene therapy: transfection and intracellular
trafficking in RPE cells. Int J Pharm 2008; 360: 177-
83.
39. Ruiz de Garibay AP, Solinís MA, Rodríguez-Gascón
A, Ganjian H, Fuchs R. Role of endocytic uptake in
transfection efficiency of solid lipid nanoparticles-
based nonviral vectors. J Gene Med 2013; 15: 427-40.
40. Delgado D, del Pozo-Rodríguez A, Solinís MA,
Gascón A.R. Understanding the mechanism of
protamine in solid lipid nanoparticle-based
lipofection: the importance of the entry pathway. Eur J
Pharm Biopharm 2011; 79: 495-502.
41. Biegeleisen K. The probable structure of the
protamina-DNA complex. J Theor Biol 2006; 241:
533-40.
42. Vighi E, Montanari M, Ruozi B, Tosi G, Magli A, Leo
E. Nuclear localization of cationic solid lipid
nanoparticles containing protamine as transfection
promoter. Eur J Pharm Biopharm 2010; 76: 384-93.
43. del Pozo-Rodríguez A, Delgado D, Solinís MA,
Gascón AR, Pedraz JL. Solid lipid nanoparticles:
formulation factors affecting cell transfection
capacity. Int J Pharm 2007; 339: 261-8.
44. del Pozo-Rodríguez A, Delgado D, Gascón AR, Solinís
MÁ. Lipid nanoparticles as drug/gene delivery
systems to the retina. J Ocul Pharmacol Ther 2013;
29: 173-88. doi: 10.1089/jop.2012.0128.
45. El-Sayed A, Khalil IA, Kogure K, Futaki S, Harashima
H. Octaarginine- and octalysine-modified
nanoparticles have different modes of endosomal
escape. J Biol Chem 2008; 283: 23450-61.
46. del Pozo-Rodríguez A, Pujals S, Delgado D, et al. A
proline-rich peptide improves cell transfection of solid
lipid nanoparticle-based non-viral vectors. J Control
Release 2009; 133: 52-9.
47. Fernández-Carneado J, Kogan MJ, Castel S, Giralt E.
Potential peptide carriers: amphipathic proline-rich
peptides derived from the N-terminal domain of
422 @Real Academia Nacional de Farmacia. Spain
gamma-zein. Angew Chem Int Ed Engl 2004; 43:
1811-4.
48. Masuda T, Akita H, Harashima H. Evaluation of
nuclear transfer and transcription of plasmid DNA
condensed with protamine by microinjection: the use
of a nuclear transfer score. FEBS Lett 2005; 579:
2143-8.
49. Delgado D, Gascón AR, del Pozo-Rodríguez A, et al.
Dextran-protamine-solid lipid nanoparticles as a non-
viral vector for gene therapy: in vitro characterization
and in vivo transfection after intravenous
administration to mice. Int J Pharm 2012; 425: 35-43.
50. Ruponen M, Rönkkö S, Honkakoski P, Pelkonen J,
Tammi M, Urtti A. Extracellular glycosaminoglycans
modify cellular trafficking of lipoplexes and
polyplexes. J Biol Chem 2001; 276: 33875-80.
51. de la Fuente M, Seijo B, Alonso MJ. Novel hyaluronic
acid-chitosan nanoparticles for ocular gene therapy.
Invest Ophthalmol Vis Sci 2008; 49: 2016-24.
52. Apaolaza PS, Delgado D, del Pozo-Rodríguez A,
Gascón AR, Solinís MÁ. A novel gene therapy vector
based on hyaluronic acid and solid lipid nanoparticles
for ocular diseases. Int J Pharm 2014; 465: 413-26.
53. Ito T, Iida-Tanaka N, Niidome T et al. Hyaluronic
acid and its derivative as a multi-functional gene
expression enhancer: protection from non-specific
interactions, adhesion to targeted cells, and
transcriptional activation. J Control Release 2006;
112: 382-8.
54. Rosenberg SA, Aebersold P, Cornetta K, et al. Gene
transfer into humans--immunotherapy of patients with
advanced melanoma, using tumor-infiltrating
lymphocytes modified by retroviral gene transduction.
N Engl J Med 1990; 323: 570-8.
55. Molday RS, Kellner U, Weber BH. X-linked juvenile
retinoschisis: clinical diagnosis, genetic analysis, and
molecular mechanisms. Prog Retin Eye Res 2012; 31:
195-212.
56. Molday LL, Hicks D, Sauer CG, Weber BH, Molday
RS. Expression of X-linked retinoschisis protein RS1
in photoreceptor and bipolar cells. Invest Ophthalmol
Vis Sci 2001; 42:8 16-25.
57. Sauer CG, Gehrig A, Warneke-Wittstock R, et al.
Positional cloning of the gene associated with X-
linked juvenile retinoschisis. Nat Genet 1997; 17:
164-70.
58. Weber BH, Schrewe H, Molday LL, et al. Inactivation
of the murine X-linked juvenile retinoschisis gene,
Rs1h, suggests a role of retinoschisin in retinal cell
layer organization and synaptic structure. Proc Natl
Acad Sci U S A 2002; 99: 6222-7.
59. Solinís MA, del Pozo-Rodríguez A, Apaolaza PS,
Rodríguez-Gascón A. Treatment of ocular disorders
by gene therapy. Eur J Pharm Biopharm 2015; 95:
331-42.
60. Delgado D, Rodríguez-Gascón A, Solinís MA,
Aspiazu MA, del Pozo-Rodríguez A, Pedraz JL.